Hans Hammers
Co-Leader of Clinical Research and Immunotherapy for the Kidney Cancer Research Program · UT Southwestern Medical Center
Credentials: · · · ·
History
2005–2009- 2002–2005
- 1992–1999
Medizinische Hochschule Luebeck, Germany
Research
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2015 · 4,745 citations
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2018 · 3,758 citations
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2015 · 999 citations
31 papers
30 papers
28 papers
- RM
26 papers
25 papers
24 papers
- MC
20 papers
18 papers
Grants
- 2010–2026
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
National Cancer Institute · P30
Project lead · $317.1K · Ut Southwestern Medical Center
Clinical trials
- 2017–2020
Principal investigator · Completed · Phase 2
University of Texas Southwestern Medical Center
- 2026–2029
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
Site PI · Recruiting · Phase 1
M.D. Anderson Cancer Center
- 2019–2028
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)